SUPERNUS PHARMACEUTICALS, INC. Cost of Goods Sold (Deprecated 2018-01-31)
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Cost of Goods Sold (Deprecated 2018-01-31) of $15.21 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsSold · last filed 2018-03-01
- SUPERNUS PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $4.16M, a 10.15% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $4.25M, a 24.01% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $3.86M, a 40.35% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $2.95M, a 44.91% increase year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2017 was $15.21M, a 26.94% increase from fiscal 2016.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2016 was $11.99M, a 42.30% increase from fiscal 2015.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $8.42M, a 46.28% increase from fiscal 2014.
- SUPERNUS PHARMACEUTICALS, INC. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $5.76M, a 421.56% increase from fiscal 2013.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $8.41M derived: sum of 2 quarters · filed 2018-03-01 | $12.27M derived: sum of 3 quarters · filed 2018-03-01 | $15.21M 10-K · filed 2018-03-01 |
| 2017-09-30 | $4.25M 10-Q · filed 2017-11-09 | $8.11M derived: sum of 2 quarters · filed 2017-11-09 | $11.06M 10-Q · filed 2017-11-09 | $14.83M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-06-30 | $3.86M 10-Q · filed 2017-08-03 | $6.81M 10-Q · filed 2017-08-03 | $10.58M derived: sum of 3 quarters · filed 2018-03-01 | $14.01M derived: sum of 4 quarters · filed 2018-03-01 |
| 2017-03-31 | $2.95M 10-Q · filed 2017-05-09 | $6.72M derived: sum of 2 quarters · filed 2018-03-01 | $10.15M derived: sum of 3 quarters · filed 2018-03-01 | $12.90M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-12-31 | $3.77M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $7.20M derived: sum of 2 quarters · filed 2018-03-01 | $9.95M derived: sum of 3 quarters · filed 2018-03-01 | $11.99M 10-K · filed 2018-03-01 |
| 2016-09-30 | $3.43M 10-Q · filed 2017-11-09 | $6.18M derived: sum of 2 quarters · filed 2017-11-09 | $8.21M 10-Q · filed 2017-11-09 | $11.01M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $2.75M 10-Q · filed 2017-08-03 | $4.79M 10-Q · filed 2017-08-03 | $7.58M derived: sum of 3 quarters · filed 2018-03-01 | $9.83M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $2.04M 10-Q · filed 2017-05-09 | $4.83M derived: sum of 2 quarters · filed 2018-03-01 | $7.08M derived: sum of 3 quarters · filed 2018-03-01 | $8.84M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $2.79M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $5.04M derived: sum of 2 quarters · filed 2018-03-01 | $6.80M derived: sum of 3 quarters · filed 2018-03-01 | $8.42M 10-K · filed 2018-03-01 |
| 2015-09-30 | $2.25M 10-Q/A · filed 2017-01-20 | $4.01M derived: sum of 2 quarters · filed 2017-01-23 | $5.63M 10-Q/A · filed 2017-01-20 | $7.91M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $1.76M 10-Q/A · filed 2017-01-23 | $3.38M 10-Q/A · filed 2017-01-23 | $5.66M derived: sum of 3 quarters · filed 2017-03-16 | $6.98M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | $1.62M 10-Q/A · filed 2017-01-20 | $3.90M derived: sum of 2 quarters · filed 2017-03-16 | $5.22M derived: sum of 3 quarters · filed 2017-03-16 | $6.88M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | $2.28M derived: 10-K 12 month − 10-Q/A 9 month · filed 2017-03-16 | $3.60M derived: sum of 2 quarters · filed 2017-03-16 | $5.26M derived: sum of 3 quarters · filed 2017-03-16 | $5.76M 10-K · filed 2017-03-16 |
| 2014-09-30 | $1.32M 10-Q/A · filed 2017-01-20 | $2.98M derived: sum of 2 quarters · filed 2017-01-20 | $3.48M 10-Q/A · filed 2017-01-20 | $4.54M derived: sum of 4 quarters · filed 2017-01-20 |
| 2014-06-30 | $1.66M 10-Q · filed 2015-08-07 | $2.15M 10-Q · filed 2015-08-07 | $3.22M derived: sum of 3 quarters · filed 2017-01-20 | $3.25M derived: sum of 4 quarters · filed 2017-01-20 |
| 2014-03-31 | $494.00K 10-Q · filed 2015-05-06 | $1.56M derived: sum of 2 quarters · filed 2017-01-20 | $1.59M derived: sum of 3 quarters · filed 2017-01-20 | $1.60M derived: sum of 4 quarters · filed 2017-01-20 |
| 2013-12-31 | $1.07M derived: 10-K/A 12 month − 10-Q 9 month · filed 2017-01-20 | $1.10M derived: sum of 2 quarters · filed 2017-01-20 | $1.10M derived: sum of 3 quarters · filed 2017-01-20 | $1.10M 10-K/A · filed 2017-01-20 |
| 2013-09-30 | $33.00K 10-Q · filed 2014-11-12 | $37.00K derived: sum of 2 quarters · filed 2014-11-12 | $37.00K 10-Q · filed 2014-11-12 | |
| 2013-06-30 | $4.00K 10-Q · filed 2014-08-12 | $4.00K 10-Q · filed 2014-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |